Association Study of Polymorphisms rs4552569 and rs17095830 and the Risk of Ankylosing Spondylitis in a Taiwanese Population

James Cheng-Chung Wei1,2, Yu-Wen Hsu3, Kuo-Sheng Hung4, Ruey-Hong Wong5, Chun-Huang Huang5, Yi-Tzu Liu3, Yuh-Cherng Guo6, Shiro Ikegawa7, Wei-Chiao Chang3,8*

1 Division of Allergy, Immunology and Rheumatology, Department of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 2 Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, 3 Department of Clinical Pharmacy, School of Pharmacy, Taipei Medical University, Taipei, Taiwan, 4 Department of Neurosurgery, Center of Excellence for Clinical Trial and Research, Graduate Institute of Injury Prevention and Control, Taipei Medical University, Wan Fang Medical Center, Taipei, Taiwan, 5 Department of Public Health, Chung Shan Medical University, Taichung, Taiwan, 6 Department of Neurology, Changhua Christian Hospital, Changhua, Taiwan, 7 Laboratory for Bone and Joint Diseases, Center for Genomic Medicine, RIKEN, Tokyo, Japan, 8 Department of Pharmacy, Taipei Medical University-Wanfang Hospital, Taipei, Taiwan

Abstract

Ankylosing spondylitis (AS) is a chronic inflammation of the sacroiliac joints, spine and peripheral joints. However, the development of ankylosing spondylitis is unclear. Human leukocyte antigens HLA-B27 and ERAP1 have been widely reported to be associated with AS susceptibility. A recent genome-wide association study (GWAS) showed that two new susceptibility loci between EDIL3 and HAPLN1 at 5q14.3 (rs4552569) and within ANO6 at 12q12 (rs17095830) contribute to the risk of AS in Han Chinese. In this study, we enrolled 475 AS patients and 475 healthy subjects to assess whether these genetic variations contribute to the susceptibility and severity of AS in Taiwanese population. The correlation between genetic polymorphisms, AS activity indexes, (namely, BASDAI, BASFI and BAS-G) and AS complications (uveitis and inflammatory bowel disease) were tested using the markers, rs4552569 and rs17095830. Although no association between rs4552569/rs17095830 genetic polymorphisms and AS susceptibility/severity was found, a significant association between rs17095830 and inflammatory bowel disease was observed in a Taiwanese population.

Introduction

Ankylosing spondylitis (AS), a chronic inflammation disorder, affects the sacroiliac joints, lumbar spine, and peripheral joints [1]. It occurs predominately in men than in women. [2] The development of AS has not been completely clarified. Many mechanisms are still ambiguous and less understood. AS is strongly associated with the human leukocyte antigen HLA-B27 gene [3], but HLA-B27 accounts for only 16% of the genetic variability in AS [4]. Compared with healthy subjects, AS patients show higher expression of circulating CD4+ T cells and CD8+ T cells [5–6]; therefore, the abnormal expression of these T cells may also be associated with AS.

It has been proven that HLA-B60, B61 and IL-1, and IL-23R play an important role in AS pathogenesis [7,8,9]. The combined genotypes of PD-1 G-536A, PD-L1 A8925C and PD-L2 C47103T show an association with AS development [10]. To elucidate the complexity of AS, the identification of genetic factors related to AS susceptibility may be useful. A recent genome-wide association study (GWAS) indicated that two new susceptibility loci between EDIL3 and HAPLN1 at 5q14.3 (rs4552569) and within ANO6 at 12q12 (rs17095830) contribute to the risk of AS in Han Chinese [11].

In this study, we assessed whether these genetic variations contribute to the susceptibility of AS in the Taiwanese population. We further investigated the genetic association with AS complications (uveitis and inflammatory bowel disease) and AS activity (BASDAI, BASFI, and BAS-G) by using the markers of rs4552569 and rs17095830. Our results imply that rs4552569 and rs17095830 may not be associated with the susceptibility of AS. However, a significant association between ANO6 polymorphism rs17095830 and inflammatory bowel disease (IBD) was observed.

Materials and Methods

Patients studied

AS patients who fulfilled the selection criteria, were solicited sequentially at Chung Shan Medical University Hospital in Taichung, Taiwan. Before any data, we collected the informed consent from the respondents. AS patients were recruited by three selection criteria: (a) patients aged 16–65 years; (b) cognitive performance not influenced by other diseases such as dementia;
and (c) AS diagnosis by the modified New York criteria [12]. AS diagnosed by a qualified rheumatologist and sacroilitis was confirmed by a qualified radiologist. The detailed clinical history included extraspinal manifestations, age on initial symptom, and family history of AS. When the first symptom (axial symptom, peripheral arthritis, uveitis or enthesitis) had developed, age of AS symptom onset was defined as the time. Peripheral arthritis was defined as the presence of at least one swollen joint. The presence of the inflammatory condition of the colon and small intestine, including ulcerative colitis and Crohn’s disease was defined as inflammatory bowel disease (IBD) (distinct from irritable bowel syndrome). Uveitis was defined as the inflammation of the middle layer of the eye, which involved patterns as unilateral, bilateral, or alternative. These symptoms were recorded in medical record reviews, and were ascertained by the rheumatologist, ophthalmologist and gastroenterologist. All of AS patients in this study have sacroilitis. The study was approved by the Institute Review Board of Chung Shan Medical University Hospital, and the design of the work and final report conformed to the Declaration of Helsinki. All the subjects gave the written consent form.

### Bath Ankylosing Spondylitis Indices

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath Ankylosing Spondylitis Global (BAS-G) were applied to evaluate the disease activity, physical function and global wellbeing, respectively. The modified Chinese versions of BASDAI, BASFI, and BAS-G have good intra-class correlation and Cronbach's alpha [13].

### Genotyping

Genotyping for two SNPs was carried out using the TaqMan Allelic Discrimination Assay (Applied Biosystems, Foster city, CA) as our previous report [14]. The polymerase chain reaction (PCR) was using a 96-well microplate with the ABI9700 Thermal Cycler. After PCR, the System SDS software version 1.2.3 was used to detected and analyzed fluorescence.

### Statistical analysis

JMP 8.0 for Windows was used for analysis. Hardy-Weinberg equilibrium was assessed by the \( \chi^2 \) test with 1 degree of freedom. The statistical differences between the patient and control groups, in genotype and allele frequency were analyzed by the chi-square test. Among different genotypes in AS patients, analysis of variance (ANOVA) was used to compare the mean of continuous variables (BASDAI, BASFI, and BAS-G). Multiple regression analysis was used to adjust for age, sex and disease duration. The Bonferroni test was used to correct for multiple tests. It is considered as significant when a \( P \) value is less than 0.025.

### Results

No association of rs4552569 and rs17095830 genetic polymorphisms in AS susceptibility

A total of 475 patients with AS and 475 healthy subjects were recruited. All AS patients were diagnosed according to the modified New York criteria (mean age, 39 years; men %, 68). In our AS cohort, 90.7% were HLA-B27 positive. Potential controls were randomly selected from sequential patients with no

### Table 1. Genotype and allele frequencies of rs4552569 and rs17095830 in controls and patients with AS.

| Genotype | Case (%) (n = 475) | Control (%) (n = 475) | Allele | Case (%) (n = 475) | Control (%) (n = 475) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|-------------------|----------------------|--------|-------------------|----------------------|------------------|------------------|------------------|-----------------|
| rs4552569 | CC                | 32 (6.8)             | 40 (9.1) | C                 | 258 (27.4)           | 245 (27.9)       | 0.3033           | 0.6754           | 0.1988          | 0.8275          |
|         | CT                | 194 (41.3)           | 165 (37.6) | T               | 682 (72.6)           | 633 (72.1)       |                  |                  |                 |                 |
|         | TT                | 244 (51.9)           | 234 (53.3) |                  |                      |                  |                  |                  |                 |                 |
| rs17095830 | GG               | 6 (1.3)              | 5 (1.1)   | G                | 96 (10.2)            | 77 (8.7)         | 0.5266           | 0.2583           | 0.8404          | 0.2731          |
|         | AG                | 84 (17.8)            | 67 (15.1) | A                | 848 (89.8)           | 811 (91.3)       |                  |                  |                 |                 |
|         | AA                | 382 (80.9)           | 372 (83.8) |                  |                      |                  |                  |                  |                 |                 |

**Table 2. Genotype and allele frequencies of rs4552569 and rs17095830 in AS patients with or without uveitis.**

| Genotype | Uveitis (%) (n = 46) | Without (%) (n = 360) | Allele | Uveitis (%) (n = 46) | Without (%) (n = 360) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|---------------------|-----------------------|--------|---------------------|-----------------------|------------------|------------------|------------------|-----------------|
| rs4552569 | CC                  | 3 (6.7)               | 25 (7.0) | C                   | 30 (33.3)            | 192 (26.9)       | 0.2085           | 0.0944           | 0.9335          | 0.1976          |
|         | CT                  | 24 (53.3)             | 142 (39.8) | T               | 60 (66.7)           | 522 (73.1)       |                  |                  |                 |                 |
|         | TT                  | 18 (40.0)             | 190 (53.2) |                  |                      |                  |                  |                  |                 |                 |
| rs17095830 | GG                | 0 (0.0)               | 5 (1.4)   | G                  | 7 (7.8)             | 73 (10.2)        | 0.6762           | 0.5764           | 0.4250          | 0.4697          |
|         | AG                  | 7 (15.6)              | 63 (17.6) | A                  | 83 (22.2)           | 643 (89.8)       |                  |                  |                 |                 |
|         | AA                  | 38 (84.4)             | 290 (81.0) |                  |                      |                  |                  |                  |                 |                 |

doi:10.1371/journal.pone.0052801.t001
doi:10.1371/journal.pone.0052801.t002
significant medical histories or abnormal laboratory results. All individuals were Taiwanese and gave informed written consent to participate in the study. As shown in the Table 1, no significant association between the genetic variants (rs4552569/rs17095830) and AS was observed. We also considered 12 combinatorial patterns of these two SNPs (as shown in Figure S1) and performed association studies of the susceptibility in AS patients, however, none of significant association was observed (data not shown).

rs17095830 associated with the inflammatory bowel disease in AS patients

We further investigated whether these two genetic polymorphisms associated with the complications (uveitis and IBD) and clinical phenotypes including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath Ankylosing Spondylitis Global Index (BAS-G). As shown in Table 2, we failed to find the association between two SNPs and uveitis. However, a significant association between AN06 polymorphism rs17095830 and inflammatory bowel disease (IBD) was found even after Bonferroni correction (Table 3). Importantly, if the combinatorial effects by two locus model (rs4552569 and rs17095830) were considered, a borderline association ($P = 0.0266$) was obtained in BASDAI (Table 4).

No association of rs4552569 and rs17095830 genetic polymorphisms in controls and patients among HLA-B27 (+) with AS

We performed analysis between HLA-B27 (+) AS patients and controls with genetic variants rs4552569 and rs17095830, but we did not observe a significant association (Table 5).

Table 3. Genotype and allele frequencies of rs4552569 and rs17095830 in AS patients with or without inflammatory bowel disease (IBD).

| Genotype | IBD (%) (n = 23) | Without (%) (n = 400) | Allele | IBD (%) (n = 23) | Without (%) (n = 400) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|-----------------|----------------------|--------|-----------------|----------------------|-----------------|-----------------|-----------------|----------------|
| rs4552569 |                 |                      |        |                 |                      |                 |                 |                 |                 |
| CC       | 3 (13.0)        | 26 (6.6)             | C      | 14 (30.4)       | 218 (27.5)           | 0.4524          | 0.9510          | 0.2341          | 0.6681          |
| CT       | 8 (34.8)        | 166 (41.9)           | T      | 32 (69.6)       | 574 (72.5)           |                 |                 |                 |                 |
| TT       | 12 (52.2)       | 204 (51.5)           |        |                 |                      |                 |                 |                 |                 |
| rs17095830 |               |                      |        |                 |                      |                 |                 |                 |                 |
| GG       | 0 (0.0)         | 6 (1.5)              | G      | 9 (19.6)        | 78 (9.8)             | 0.0213*         | 0.0131*         | 0.5526          | 0.0350          |
| AG       | 9 (39.1)        | 66 (16.6)            | A      | 37 (80.3)       | 716 (90.2)           |                 |                 |                 |                 |
| AA       | 14 (60.9)       | 325 (81.9)           |        |                 |                      |                 |                 |                 |                 |

*Significant ($P < 0.025$) values are in bold.

doi:10.1371/journal.pone.0052801.t003

Table 4. Difference in the scores of BASDAI, BASFI, and BAS-G among AS patients stratified by rs4552569 and rs17095830 genotypes.

| SNP       | Genotype | BASDAI | BASFI | BAS-G |
|-----------|----------|--------|-------|-------|
| rs4552569 |          |        |       |       |
| CC        | 4.89±1.92| 2.24±2.05| 4.38±2.46|
| CT        | 4.34±2.22| 2.07±2.22| 4.52±2.79|
| TT        | 4.20±2.20| 2.01±2.18| 4.27±2.75|
| Unadjusted P-value | 0.2393 | 0.8297 | 0.6436 |
| Adjusted P-value | 0.2387* | 0.7625* | 0.6405* |
| rs17095830 |          |        |       |       |
| GG        | 3.91±3.23| 2.93±4.39| 4.12±4.62|
| AG        | 4.62±2.22| 2.09±2.08| 4.58±2.94|
| AA        | 4.26±2.18| 2.04±2.19| 4.36±2.68|
| Unadjusted P-value | 0.3610 | 0.6202 | 0.7779 |
| Adjusted P-value | 0.3602* | 0.9494* | 0.7757* |

Two-locus model

|                  | Unadjusted P-value | Adjusted P-value |
|------------------|--------------------|------------------|
| High-risk group  | 4.34±2.19*         | 4.49±2.94*       |
| Low-risk group   | 4.01±2.17*         | 4.36±2.71*       |
| Unadjusted P-value | 0.0266             | 0.7235           |
| Adjusted P-value | 0.0264*            | 0.7222*          |

Data represent means ± S.D.

*Adjusted the effects of age and sex.

1Adjusted the effects of age, sex and disease duration. 0.025 ≤ P < 0.05 values are in bold.

1AS patients with the CC genotype of rs4552569, GG genotype of rs17095830 or heterozygous at both loci were classified into high-risk group and the others were classified into low-risk group.

doi:10.1371/journal.pone.0052801.t004
AS patients, we examined the complications of AS and the association with rs4552569 and rs17095830, however our result showed no statistic significance after Bonferroni correction (Table 6 and Table 7). Our results also revealed no association in the BASDAI, BASFI, and BAS-G scores among HLA-B27 (+) AS patients with the rs4552569 and rs17095830 genotypes (Table 8). Analysis by two locus model didn’t improve the significance (Table 8). Thus, our results suggest that rs4552569 and rs17095830 may not associate with AS in a Taiwanese population.

Discussion

The first Genome-wide association studies (GWAS) of AS in a European population found an association of two new genetic loci 2p15 (rs10865331) and 21q22 (rs2242944) with AS development, as well as in the SNPs ANTXR2 (rs4333130) and ILIR2 (rs2310173), and it confirmed the previously reported associations with rs4552569 and rs17095830 genetic polymorphisms are not associated with AS development and clinical manifestations in the Taiwanese. In the Taiwanese population, the susceptibility genetic polymorphism of the interleukin-12B (IL-12B) +1188A/C, which encodes a p10 subunit common to IL-12 and IL-23, may be a risk factor for AS development [20]. Wei et al. [14] also observed that ORAI1 haplotypes are associated with the development of HLA-B27 positive AS patients. However, these associations have not been validated in the Han Chinese population yet.

The reasons for these inconsistent results in Han Chinese and Taiwanese populations are unknown. Our enrollment criterion for AS patients was a diagnosis by an experienced rheumatologist according to the modified New York criteria (1984), similar to the Han Chinese in the GWAS. Potential healthy controls were randomly selected from patients sequentially admitted to the same medical center for general physical examinations. They resided in the same geographical areas as the AS patients and had no significant medical history or abnormal laboratory results. In the present study, the frequency of rs4552569 G allele and rs17095830 T allele in normal controls (27.9% and 8.7%, respectively) is close to the present study, the frequency of rs4552569 C allele and rs17095830 G allele in normal controls (27.9% and 8.7%, respectively) is close to

Table 5. Genotype and allele frequencies of rs4552569 and rs17095830 in controls and patients among HLA-B27 (+) with AS.

| Genotype | Case (%) (n = 431) | Control (%) (n = 475) | Allele | Case (%) (n = 431) | Control (%) (n = 475) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|-------------------|----------------------|--------|-------------------|----------------------|-----------------|-----------------|-----------------|----------------|
| rs4552569 |                   |                      |        |                   |                      |                 |                 |                 |                 |
| CC       | 27 (6.3)          | 40 (9.1)             | C      | 231 (27.1)        | 245 (27.9)           | 0.2160          | 0.7259          | 0.1271          | 0.7124         |
| CT       | 177 (41.6)        | 165 (37.6)           | T      | 621 (72.9)        | 633 (72.1)           |                 |                 |                 |                 |
| TT       | 222 (52.1)        | 234 (53.3)           |        |                   |                      |                 |                 |                 |                 |
| rs17095830 |                  |                      |        |                   |                      |                 |                 |                 |                 |
| GG       | 5 (1.2)           | 5 (1.1)              | G      | 88 (10.3)         | 77 (8.7)             | 0.4588          | 0.2200          | 0.9535          | 0.2510         |
| AG       | 78 (18.2)         | 67 (15.1)            | A      | 768 (89.7)        | 811 (91.3)           |                 |                 |                 |                 |
| AA       | 345 (80.6)        | 372 (83.8)           |        |                   |                      |                 |                 |                 |                 |

Table 6. Genotype and allele frequencies of rs4552569 and rs17095830 in HLA-B27 (+) AS patients with or without uveitis.

| Genotype | Uveitis (%) (n = 39) | Without (%) (n = 330) | Allele | Uveitis (%) (n = 39) | Without (%) (n = 330) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|---------------------|-----------------------|--------|---------------------|-----------------------|-----------------|-----------------|-----------------|----------------|
| rs4552569 |                     |                       |        |                     |                       |                 |                 |                 |                 |
| CC       | 2 (5.3)             | 21 (6.4)              | C      | 23 (30.3)           | 174 (26.6)            | 0.5212          | 0.3222          | 0.7808          | 0.4966         |
| CT       | 19 (50.0)           | 132 (40.4)            | T      | 53 (69.7)          | 480 (73.4)            |                 |                 |                 |                 |
| TT       | 17 (44.7)           | 174 (53.2)            |        |                     |                       |                 |                 |                 |                 |
| rs17095830 |                    |                       |        |                     |                       |                 |                 |                 |                 |
| GG       | 0 (0.0)             | 4 (1.2)               | G      | 5 (6.6)            | 67 (10.2)             | 0.5854          | 0.3641          | 0.4937          | 0.3138         |
| AG       | 5 (13.2)            | 59 (18.0)             | A      | 71 (93.4)          | 589 (89.8)            |                 |                 |                 |                 |
| AA       | 33 (86.8)           | 265 (80.8)            |        |                     |                       |                 |                 |                 |                 |

doi:10.1371/journal.pone.0052801.t005
doi:10.1371/journal.pone.0052801.t006
to that found in the Han Chinese GWAS controls (28.0% and 10.0%, respectively) [11]. These findings confirm the validity of the genotyping methodology used in this study. Selection bias may have occurred when AS patients with active or inactive disease were enrolled. Because our subjects were adults, these results do not apply to juvenile AS patients. Referral bias was possible, since our data were collected from a single medical center. There is also a concern regarding the relatively smaller sample size in our study. We recognize that small numbers of subjects may limit the statistical power (with 20% statistical power) to detect a small increase in risk. The sample size may result from the limited population in Taiwan. Therefore, larger cohort studies in another population are necessary to provide additional regarding our findings. In summary, rs4552569 and rs17095830 genetic polymorphisms may not be susceptibility factors for AS development and clinical manifestations in the Taiwanese.

### Table 7. Genotype and allele frequencies of rs4552569 and rs17095830 in HLA-B27 (+) AS patients with or without inflammatory bowel disease (IBD).

| Genotype | IBD (%) (n = 21) | Without (%) (n = 365) | Allele | IBD (%) (n = 21) | Without (%) (n = 365) | Genotype P Value | Dominant P Value | Recessive P Value | Allelic P Value |
|----------|-----------------|----------------------|--------|-----------------|----------------------|------------------|------------------|------------------|----------------|
| rs4552569 | CC 3 (14.3) | 21 (5.8) | C 14 (33.3) | 193 (26.7) | 0.2986 | 0.6728 | 0.1200 | 0.3494 |
|         | CT 8 (38.1) | 151 (41.8) | T 28 (66.7) | 529 (73.3) |          |                |                  |                  |
|         | TT 10 (47.6) | 189 (52.4) |        |                |          |                |                  |                  |
| rs17095830 | GG 0 (0.0) | 5 (1.4) | G 8 (19.0) | 71 (9.8) | 0.0443 | 0.0250 | 0.5877 | 0.0556 |
|         | AG 8 (38.1) | 61 (16.8) | A 34 (81.0) | 653 (90.2) |          |                |                  |                  |
|         | AA 13 (61.9) | 296 (81.8) |        |                |          |                |                  |                  |

We recognize that small numbers of subjects may limit the statistical power (with 20% statistical power) to detect a small increase in risk. The sample size may result from the limited population in Taiwan. Therefore, larger cohort studies in another population are necessary to provide additional regarding our findings. In summary, rs4552569 and rs17095830 genetic polymorphisms may not be susceptibility factors for AS development and clinical manifestations in the Taiwanese.

### Table 8. Difference in the scores of BASDAI, BASFI, and BAS-G among HLA-B27 (+) with AS patients stratified by rs4552569 and rs17095830 genotypes.

| SNP | Genotype | BASDAI | BASFI | BAS-G |
|-----|----------|--------|-------|-------|
| rs4552569 | CC | 4.56±1.81 | 2.13±2.12 | 4.13±2.52 |
|       | CT | 4.29±2.17 | 2.03±2.20 | 4.52±2.74 |
|       | TT | 4.25±2.20 | 2.04±2.21 | 4.31±2.77 |
|       | Unadjusted P-value | 0.7797 | 0.9762 | 0.6489 |
|       | Adjusted P-value | 0.7790 | 0.9082 | 0.6448 |
| rs17095830 | GG | 3.01±2.64 | 1.90±4.03 | 2.94±4.03 |
|       | AG | 4.61±2.21 | 2.06±2.02 | 4.68±2.88 |
|       | AA | 4.25±2.15 | 2.06±2.24 | 4.36±2.70 |
|       | Unadjusted P-value | 0.1696 | 0.9876 | 0.3200 |
|       | Adjusted P-value | 0.1685 | 0.9745 | 0.3146 |

**Two-locus model**

|                | High-risk group | Low-risk group |
|----------------|-----------------|----------------|
| Unadjusted P-value | 0.1738 | 0.1729 |
| Adjusted P-value   | 0.9784 | 0.9530 |

Data represent means ± S.D.

1 Adjusted the effects of sex.
2 Adjusted the effects of age, sex and disease duration.
3 AS patients with the CC genotype in rs4552569, GG genotype in rs17095830 or heterozygous at both loci were classified into high-risk group and the others were classified into low-risk group.

doi:10.1371/journal.pone.0052801.t007
Supporting Information

Figure S1 We examined 12 combinatorial patterns in rs4552569 and rs17095830 gene-gene interaction.

Acknowledgments

The authors are grateful to Prof. William Klitz (University of California, Berkeley) for reading the manuscript and offering suggestions.

Author Contributions

Conceived and designed the experiments: JW KSH RHW YWH CHH SI WCC. Performed the experiments: YWH CHH YTL. Analyzed the data: JW RHW YWH CHH YCG KSH SI WCC. Contributed reagents/materials/analysis tools: JW RHW YCG KSH WCC. Wrote the paper: JW RHW YWH YTL WCC.

References

1. Braun J, Sieper J (2007) Ankylosing spondylitis. Lancet 369: 1379–1390.
2. Calin A, Brophy S, Blake D (1999) Impact of sex on inheritance of ankylosing spondylitis: a cohort study. Lancet 354: 1687–1690.
3. Breherton IA, Hart FD, Nicholls A, Califfrey M, James DC, et al. (1973) Ankylosing spondylitis and HLA-27. Lancet 1: 904–907.
4. Khan MA, Ball EJ (2002) Genetic aspects of ankylosing spondylitis. Best Pract Res Clin Rheumatol 16: 675–690.
5. Duffner C, Goldberger C, Falkenbach A, Wurzner R, Falkensammer B, et al. (2003) Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28− T cells in ankylosing spondylitis. Arthritis Res Ther 5: R292–300.
6. Schirmer M, Goldberger C, Wurzner R, Duffner C, Pfeiffer KP, et al. (2002) Circulating cytotoxic CD8(+CD28(−)) T cells in ankylosing spondylitis. Arthritis Res 4: 71–76.
7. Safary E, Pazar B, Csongei V, Jaromi L, Polgar N, et al. (2009) Variants of the IL23R gene are associated with ankylosing spondylitis but not with Sjogren syndrome in Hungarian population samples. Scand J Immunol 70: 60–74.
8. Wei JC, Tsai WC, Lin HS, Tsai CY, Chou CT (2004) HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Chinese patients. Rheumatology (Oxford) 43: 839–842.
9. Guo ZS, Li C, Lin ZM, Huang JX, Wei QJ, et al. (2010) Association of IL-4 gene complex members with ankylosing spondylitis in Chinese Han population. Int J Immunogenet 37: 33–37.
10. Huang CH, Wong RH, Wei JC, Tsay MD, Chen WC, et al. (2011) Effects of genetic polymorphisms of programmed death 1 and its ligands on the development of ankylosing spondylitis. Rheumatology (Oxford) 50: 1089–1013.
11. Liu Z, Bei JX, Shen M, Li Q, Liao Z, et al. (2012) A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis. Nat Genet 44: 73–77.
12. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27: 361–366.
13. Wei JC, Wong RH, Huang JH, Yu CT, Chou CT, et al. (2007) Evaluation of internal consistency and re-test reliability of Bath ankylosing spondylitis indices in a large cohort of adult and juvenile spondylitis patients in Taiwan. Clin Rheumatol 26: 1685–1691.
14. Wei JC, Yen JH, Joo SH, Chen WC, Wang YS, et al. (2011) Association of ORAI1 haplotypes with the risk of HLA-B27 positive ankylosing spondylitis. PLoS One 6: e20426.
15. Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. (2010) Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet 42: 123–127.
16. Evans DM, Spencer CC, Pounton JJ, Su Z, Harvey D, et al. (2011) Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43: 761–767.
17. Chen C, Zhang X, Wang Y (2012) ANTXR2 and IL-1R2 polymorphisms are not associated with ankylosing spondylitis in Chinese Han population. Rheumatol Int 32: 15–19.
18. Davidson SI, Wu X, Lin Y, Wei M, Danoy PA, et al. (2009) Association of ERAP1, but not IL23R, with ankylosing spondylitis in a Han Chinese population. Arthritis Rheum 60: 3263–3268.
19. Davidson SI, Lin Y, Danoy PA, Wu X, Thomas GP, et al. (2011) Association of STAT3 and TNFRSF1A with ankylosing spondylitis in Han Chinese. Ann Rheum Dis 70: 289–292.
20. Wong RH, Wei JC, Huang CH, Lee HS, Chou SY, et al. (2012) Association of IL-12B genetic polymorphism with the susceptibility and disease severity of ankylosing spondylitis. J Rheumatol 39: 135–140.